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Summary The effects of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase
(HMG-CoA reductase), on oxidative stress resistance and the protective effects of coenzyme
Q (CoQ) were investigated. When simvastatin was administered orally to mice, the levels of
oxidized and reduced CoQ9 and CoQ10 in serum, liver, and heart, decreased significantly when
compared to those of control. The levels of thiobarbituric acid reactive substances induced by
Fe2+-ascorbate in liver and heart mitochondria also increased significantly with simvastatin.
Furthermore, cultured cardiac myocytes treated with simvastatin exhibited less resistance to
oxidative stress, decreased time to the cessation of spontaneous beating in response to H2O2
addition, and decreased responsiveness to electrical field stimulation. These results suggested
that oral administration of simvastatin suppresses the biosynthesis of CoQ, which shares the
same biosynthesis pathway as cholesterol up to farnesyl pyrophosphate, thus compromising
the physiological function of reduced CoQ, which possesses antioxidant activity. However,
these undesirable effects induced by simvastatin were alleviated by coadministering CoQ10
with simvastatin to mice. Simvastatin also reduced the activity of NADPH-CoQ reductase, a
biological enzyme that converts oxidized CoQ to the corresponding reduced CoQ, while CoQ10
administration improved it. These findings may also support the efficacy of coadministering
CoQ10 with statins.
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Introduction
Hypercholesterolemia is a well-known risk factor for
coronary heart disease and arteriosclerosis. 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA), the late-limiting
enzyme in the biosynthesis of cholesterol through the
mevalonate pathway, converts HMG-CoA, a trimer of acetyl
CoA molecules generated from fatty acid oxidation, to
mevalonic acid, which is then further metabolized to eventually
produce cholesterol [1]. Among various drugs developed to
reduce serum cholesterol levels and subsequent risk for
coronary events, HMG-CoA reductase inhibitors (statins),
have proven to be extremely useful drugs [2–5].
While statins are very clinically effective drugs, adverse
reactions such as rhabdomyolysis [6, 7] have been reported.
Adverse reactions often affect tissues and cells with high
energy metabolism, such as skeletal muscles, myocardium
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and smooth muscles, and to date, ultrastructural changes,
including mitochondrial dysfunction [8,  9] and swelling,
increased serum creatine kinase, induction of necrosis [10] or
apoptosis [11–15], and abnormalities in calcium homeostasis
[16] have been reported. However, the contributing factors
and protective effects have not been elucidated.
Coenzyme Q (CoQ) is an essential carrier for the mito-
chondrial electron transport system and plays an important
role in energy production. Exogenous CoQ10 has been shown
to improve energy metabolism and activate energy production
by cardiac myocytes. CoQ is distributed not only in mito-
chondria, but also in other subcellular fractions [17–19], and
some CoQ always presents as reduced CoQ (H2CoQ) [18].
H2CoQ is unstable when exposed to air, and can easily be
oxidized into oxidized CoQ. In this manner, chemically
unstable H2CoQ is thought to exist in the body to serve as an
antioxidant. We have reported previously [20–22] that a
novel cytosolic NADPH-CoQ reductase is responsible for
the reduction of CoQ10 to H2CoQ10 in biomembranes.
Furthermore, we observed that prolonged supplementation
with CoQ10 caused a significant increase in the NADPH-CoQ
reductase activity, and protected partially hepatotoxicity
induced by carbon tetrachloride and H2O2. In addition,
enhanced levels of H2CoQ10 and NADPH-CoQ reductase
activity showed more resistant to oxidative stress than
those of normal levels. These results suggested that H2CoQ10
with NADPH-CoQ reductase constituted a fundamental
defense system against oxidative stress in cellular membrane.
According to some reports, another reductases such as
NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase)
[23, 24], thiredoxin reductase [25] and lipoamide dehydro-
genase 1 [26, 27] may also involve in the reduction of CoQ
to H2CoQ. The in vitro experiments using low-density lipo-
protein (LDL) [28,  29], biological membranes [30] or
lecithin liposome membranes [31, 32] have clarified that
H2CoQ possesses potent antioxidant activity. To date, two
mechanisms for the antioxidant activities of H2CoQ have
been clarified. In one mechanism, H2CoQ directly eliminates
lipid peroxyl radicals [31,  32], and in the other, H2CoQ
indirectly acts as an antioxidant by regenerating α-tocopherol
from α-tocopheroxyl radicals formed by a reaction between
α-tocopherol and lipid peroxyl radicals (α-tocopherol-
saving action). It has been clarified that H2CoQ exhibits
potent antioxidant activity through these two mechanisms.
CoQ is supplied exogenously through diet [33] or
endogenously through biosynthesis [34,  35]. Therefore,
supply reduction in either exogenous or endogenous CoQ
may affect its physiological functions. Because cholesterol
and CoQ share the same biosynthesis pathway until farnesyl
pyrophosphate [34, 35], inhibition of HMG-CoA reductase,
which is the rate-limiting enzyme in cholesterol bio-
synthesis, is likely to affect the metabolism and physio-
logical functions of CoQ, including H2CoQ [35]. In fact,
many investigators have pointed out that statin administration
lowers CoQ in serum (plasma) [9, 36–38] and tissue [36],
and that statins hinder normal function of the heart [39] and
skeletal muscles [40].
In this study, in order to administer HMG-CoA reductase
inhibitors safely and efficiently, we elucidated the change of
oxidative stress resistance induced by simvastatin and its
protective effects of CoQ10 were investigated.
Materials and Methods
Reagents
All reagents were commercially available and were of
reagent grade. The solvent for high performance liquid
chromatography (HPLC) was purchased from Wako Pure
Chemical Industries, Ltd., Osaka. Commercially available
reagent grade methanol for HPLC was used after distillation.
Authentic CoQ9 and CoQ10 for HPLC were donated by
Nisshin Pharma Inc., Tokyo. As simvastatin, 5 mg Lipovas
tablets (pharmaceutical drug, Banyu Pharmaceutical Co.
Ltd., Tokyo), and as CoQ10, 30 mg LivLon Soft Capsules
(dietary and health food, Nisshin Pharma Inc., Tokyo) were
used in the experiment for oral administration to mice. Each
compound was dissolved in drinking water and homo-
genized by ultrasonic treatment.
Animals
Ten week-old male specific pathogen-free (SPF) ICR
mice were used. To prepare cultured cardiac myocytes,
female SPF ICR mice on the fourth day of gestation were
used. All mice were purchased from SLC Japan (Shizuoka).
Simvastatin and CoQ10 were administered orally, and by
measuring daily water intake for each mouse for three days
before the study, drug solutions were prepared such that
each mouse would consume the predetermined dosages.
Simvastatin and CoQ10 were mixed in drinking water just
prior to administration, and drinking water was prepared daily.
Based on body weight, the mice were divided into four groups
of five mice each [(1) control group (no simvastatin or CoQ10),
(2) simvastatin group (1 mg/day of simvastatin), (3) CoQ10
group (3 mg/day of CoQ10), and (4) simvastatin + CoQ10
group (1 mg/day of simvastatin + 3 mg/day of CoQ10)], and
the dosage of simvastatin and CoQ10 was set as follows:
each mouse was weighed daily, and simvastatin and CoQ10
were administered for two consecutive weeks. Simvastatin
and CoQ10 were administered orally to pregnant mice from
the fourth to fifteenth day of gestation (fetal ventricular
myocardium was excised from pregnant mice on the
fifteenth day of gestation). Mice were fed Lab MR Stock
(standard feed, SLC Japan). All animal experiments were
conducted in accordance with the manual compiled by the
Kobe University Animal Ethics Committee.A. Kettawan et al.
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Cultured cardiac myocyte preparation and observation
The fetal ventricular myocardium was excised from
pregnant mice prepared as described above from the fourth
to fifteenth day of gestation, and cultured cardiac myocytes
were prepared according to the method of Goshima et al.
[41]. Cardiac myocytes were cultured using Eagle MEM
containing 10% fetal bovine serum under 5% CO2 in air at
37°C for 2 days. To avoid antioxidant contamination,
including CoQ10, originating from fetal bovine serum, cells
were washed using 10 ml of Dulbecco’s phosphate-buffered
saline twice 1 h before the study, and after replacing culture
solution with Eagle MEM free of fetal bovine serum, cells
were incubated under 5% CO2 in air at 37°C for at least
one hour. A 1- to 2-mm-diameter cardiac myocyte sheet
containing at least 104 cells was produced after cultivation
for 2 days. The spontaneous beating of cultured cardiac
myocyte sheet was measured in an incubator at 36 ± 1°C and
under 5% CO2 in air using a phase contrast microscope.
Electrical field stimulation was performed by the method of
Nakamura et al., as follows [42]: two platinum electrodes,
1 Hz, pulse length of 50 ms, and pulse amplitude of 100 V.
Preparation of mitochondria and cytosolic fraction from
mice liver and heart
Intracellular fractions of mice heart and liver were prepared
by differential centrifugation as described previously [18].
The purity of the cytosol and mitochondrial fractions was
determined by measuring their marker enzyme activities.
Measurement of total serum cholesterol level
Total serum cholesterol was measured spectrophoto-
metrically by the enzyme method [43].
Measurement of CoQ levels in serum, cytosolic fraction and
tissue
Reduced and total CoQ (sum of oxidized and reduced
CoQ) levels were measured by HPLC-electrochemical
detector in accordance with the method of Okamoto et al.
[44]. CoQ in the cytosolic fraction was expressed as pmol
per mg protein.
Measurement of lipid peroxidation induced by Fe2+-ascorbate
Lipid peroxidation was carried out using 50 mM ascorbic
acid and 5 mM FeSO4 according to the method of Takei et
al. [45]. Thiobarbituric acid reactive substances (TBARS)
were extracted using 3 ml of n-butanol and were measured
by the fluorometrical method (Ex: 515 nm, Em: 553 nm).
The standard was 1,1,3,3-tetraethoxypropane in the TBARS
assay.
Measurement of NADPH-CoQ reductase activity in cytoplasm
NADPH-CoQ activity in cytoplasm of liver and heart was
measured according to the method of Takahashi et al. [46].
This activity was expressed as the amount of CoQ10 (pmol)
reduced per minute per mg protein.
Protein content and data analysis
Protein content was determined as described by Lowry et
al. [ 47]. The Student’s unpaired t test were used for
statistical analysis and statistical significance was assigned
for any p values less than 0.05.
Results
Changes in reduced and total CoQ levels in mouse serum,
heart, liver, and their cytosolic and mitochondorial fractions
induced by simvastatin administration (Table 1)
When 1 mg/kg body weight simvastatin was orally
administered to mice everyday for two weeks, total serum
cholesterol decreased significantly when compared to controls
(no simvastatin or CoQ10). Furthermore, coadministration of
simvastatin and CoQ10 lowered serum cholesterol in a
similar manner. This result shows that CoQ10 itself does not
affect the cholesterol lowering activity of simvastatin.
Simvastatin administration significantly lowered the levels
of both serum CoQ9, the predominant homologue in mice,
and CoQ10, as compared to those of control. Furthermore,
simvastatin also singnificantly lowered reduced, oxidized
and total CoQ10 levels, and did not affect the ratio of reduced
CoQ to total CoQ.
When 3 mg/kg body weight CoQ10 was orally administered
to mice everyday for two weeks, irrespective of whether
CoQ10 was administered alone or with simvastatin, serum
levels increased by about 6-fold. These results show that
simvastatin administration does not affect the serum CoQ10
increasing level by CoQ10 administration. CoQ10 itself did
not affect the levels of serum CoQ9, the main homologue in
mice.
Like the levels of CoQ9 and CoQ10 in serum, the levels of
CoQ9 and CoQ10 in the liver and heart were significantly
lowered by simvastatin administration. Furthermore, this
lowering action was observed in mitochondrial and cytosolic
fractions of liver and heart.
Oxidative stress resistance-decreasing effects of simvastatin
Changes in oxidative stress resistance due to simvastatin
administration were evaluated using heart and liver mito-
chondria and cultured cardiac myocytes.
The TBARS levels produced using Fe2+-ascorbate in heart
mitochondria at 15 min after the start of the reaction for the
simvastatin group was significantly higher when compared
to the other groups (Table 2). At two hours after the start
of the reaction, the TBARS level (mM) in the control,
simvastatin, CoQ10 and simvastatin + CoQ10 groups was
0.67, 0.81, 0.63 and 0.66, respectively, and CoQ10 clearly
lowered significantly the TBARS level as compared to thatStatins, CoQ10 and Oxidative Stress
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of simvastatin group.
Like heart mitochondria, simvastatin administration
increased the amount of TBARS with time in liver mito-
chondria. However, unlike heart mitochondria, suppression
of TBARS by CoQ10 was not seen for the first hour of the
reaction, and significant suppression was confirmed only
after two hours (Table 3).
Changes in oxidative stress (H2O2) resistance [42] were
determined using cultured cardiac myocyte sheets prepared
from fetal ventricular myocardium obtained from pregnant
mice on oral simvastatin administration in terms of spon-
taneous beating and electrical field stimulation response
(Fig. 1). Prior to the experiment, cultured cardiac myocytes
were incubated with 10 µM CoQ10 (CoQ10-treated group) for
6 hours, 3 µM simvastatin (simvastatin-treated group) for 2
hours, or 10 µM CoQ10 for 6 hours and 3 µM simvastatin for
2 hours (simvastatin and CoQ10-cotreated group). Under
microscopic observations, in this point, any morphological
changes of cells were not observed.
When 50 µM H2O2, an active oxygen species, was added
to untreated cultured cardiac myocytes, beating stopped
after 17 min. Furthermore, immediately after cessation,
electric field stimulation was applied to the cells. When the
time for the cells to respond to the stimulation was
measured, electrical field-stimulated beating continued for
28 min. With cardiac myocytes treated by simvastatin, the
Table 1. Effect of simvastatin on serum cholesterol and Coenzyme Q contents in Serum, Heart and Liver
Administration
Control Sim CoQ10 Sim + CoQ10
Serum
Cholesterol (mg/dl) 131 ± 25 94 ± 31* 141 ± 15 90 ± 22*
Total CoQ9 (ng/ml)1 71.9 ± 3.1 60.2 ± 8.9* 75.8 ± 3.4 66.1 ± 6.4*
Reduced CoQ9 (ng/ml) 58.0 ± 2.2 48.0 ± 8.8* 62.9 ± 3.7 54.3 ± 6.8
Reduced/Total (%)2 80.4 ± 3.0 79.3 ± 3.9 83.0 ± 1.9 81.2 ± 5.5
Total CoQ10 (ng/ml)1 24.4 ± 1.3 19.3 ± 1.5** 155.3 ± 48.2** 143.7 ± 56.8**
Reduced CoQ10 (ng/ml) 19.2 ± 1.7 15.4 ± 1.5** 128.7 ± 37.3** 115.6 ± 54.2**
Reduced/Total (%)2 78.5 ± 2.6 80.1 ± 4.9 83.3 ± 2.9* 78.0 ± 6.1
Liver
Total CoQ9 (µg/g)1 39.3 ± 5.0 30.5 ± 3.1* 44.6 ± 2.8* 37.4 ± 5.6
Reduced CoQ9 (µg/g) 24.7 ± 4.9 18.4 ± 2.6* 29.8 ± 2.6* 23.5 ± 5.7
Reduced/Total (%)2 62.6 ± 6.0 60.2 ± 4.9 66.8 ± 3.7* 63.2 ± 6.7
Total CoQ10 (µg/g)1 3.3 ± 0.6 2.5 ± 0.3* 9.1 ± 1.8** 8.8 ± 2.3**
Reduced CoQ10 (µg/g) 2.0 ± 0.4 1.4 ± 0.3* 6.1 ± 1.4** 5.6 ± 1.5**
Reduced/Total (%)2 59.8 ± 4.1 57.3 ± 4.2 66.0 ± 4.9* 64.0 ± 4.1*
Mitochondria
Total CoQ101 (pmol/mg protein) 13.7 ± 1.3 10.0 ± 1.5** 21.8 ± 2.2** 17.0 ± 1.1*
Cytosol
Total CoQ101 (pmol/mg protein) 2.5 ± 0.2 2.4 ± 0.1* 3.3 ± 0.2** 3.0 ± 0.2**
Heart
Total CoQ9 (µg/g)1 214.5 ± 36.0 171.8 ± 22.4* 225.4 ± 30.9 186.1 ± 6.3*
Reduced CoQ9 (µg/g) 91.5 ± 8.7 71.0 ± 10.1* 98.8 ± 9.5 81.9 ± 8.9*
Reduced/Total (%)2 43.4 ± 5.8 41.4 ± 2.8 44.4 ± 6.4 45.0 ± 4.0
Total CoQ10 (µg/g)1 24.8 ± 5.2 21.0 ± 3.2* 26.2 ± 3.1 23.1 ± 3.4
Reduced CoQ10 (µg/g) 8.5 ± 1.2 7.0 ± 1.2* 9.9 ± 1.2 8.0 ± 1.4
Reduced/Total (%)2 35.0 ± 6.8 33.8 ± 3.3 38.2 ± 4.8 35.2 ± 6.5
Mitochondria
Total CoQ101 (pmol/mg protein) 284.8 ± 18.7 247.8 ± 17.7* 313.9 ± 11.4* 270.9 ± 20.8
Cytosol
Total CoQ101 (pmol/mg protein) 17.4 ± 0.8 13.4 ± 1.1* 16.8 ± 1.5 15.9 ± 1.0
Control: untreated group, Sim: simvastatin-treated group, CoQ10: CoQ10-treated group, Sim + CoQ10: simvastatin and
CoQ10-cotreated group. The values given are means ± SD (n =5 ) .   1 Total CoQn is the sum of both reduced and oxidized
form of CoQn. 2 Reduced CoQ10/Total CoQ10 × 100. *p<0.05, **p<0.005 vs control (untreated) group.A. Kettawan et al.
J. Clin. Biochem. Nutr.
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1 5m i n 3 0m i n 1h 2h
Control 0.46 ± 0.04e) 0.67 ± 0.03 0.61 ± 0.02d) 0.67 ± 0.01f)
Sim 0.60 ± 0.05b) 0.72 ± 0.03 0.71 ± 0.07a) 0.81 ± 0.02c)
CoQ10 0.46 ± 0.01e) 0.57 ± 0.02b), f) 0.57 ± 0.03d) 0.63 ± 0.04f)
Sim + CoQ10 0.41 ± 0.01f) 0.61 ± 0.06d) 0.60 ± 0.02d) 0.66 ± 0.02f)
Control: untreated group, Sim: simvastatin-treated group, CoQ10: CoQ10-treated group, Sim + CoQ10:
simvastatin and CoQ10-cotreated group. The values given are means ± SD (n =5 ) .   a)p<0.05, b)p<0.01,
and c)p<0.001 vs control (untreated) group at each indicated time. d)p<0.05, e)p<0.01, and f)p<0.001 vs
simvastatin-treated group at each indicated time.




1 5m i n 3 0m i n 1h 2h
Control 0.69 ± 0.02 0.86 ± 0.08 0.80 ± 0.04d) 0.85 ± 0.05c)
Sim 0.71 ± 0.03 0.89 ± 0.03 0.94 ± 0.06b) 0.94 ± 0.02a)
CoQ10 0.65 ± 0.03c) 0.74 ± 0.05a), d) 0.63 ± 0.08b), e) 0.66 ± 0.08b), e)
Sim + CoQ10 0.72 ± 0.03 0.88 ± 0.03 0.89 ± 0.06a) 0.86 ± 0.05c)
Control: untreated group, Sim: simvastatin-treated group, CoQ10: CoQ10-treated group, Sim + CoQ10:
simvastatin and CoQ10-cotreated group. The values given are means ± SD (n =5 ) .  a)p<0.05 and
b)p<0.01 vs control (untreated) group at each indicated time. c)p<0.05,  d)p<0.01, and e)p<0.001 vs
simvastatin-treated group at each indicated time.
Fig. 1.  Protective effect of Coenzyme Q10 on beating impairment of cultured cardiac myocytes induced by simvastatin. The value given
are means ± SD (n =5 ) .  a)p<0.05,  b)p<0.01, and c)p<0.001 vs control (untreated) group. d)p<0.05,  e)p<0.01, and f)p<0.001 vs
simvastatin-treated group.Statins, CoQ10 and Oxidative Stress
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length of time to cessation was 13 min, and the electric field
stimulation response time was 18 min, thus suggesting that
simvastatin lowers oxidative stress resistance. On the other
hand, CoQ10 increased the oxidative stress resistance of cardiac
myocytes, and when compared to those of simvastatin
group, spontaneous beating and electric field stimulation
response time were significantly longer. The results were the
same when 100 µM H2O2 was added to cardiac myocytes,
but the effects of CoQ10 on spontaneous beating and electric
field stimulation response time were not as great as when
50 µM H2O2 was added.
NADPH-CoQ reductase activity-lowering effect of simvas-
tatin (Fig  2)
NADPH-CoQ reductase is one of the CoQ reductases
in the cytoplasm, and we have reported previously that
NADPH-CoQ reductase activity changes due to various
oxidative stresses [48].
As shown in Fig. 2, when compared to the control group,
cytoplasmic NADPH-CoQ reductase activity in the liver
and heart in the simvastatin group were significantly lower
when compared to those of control. CoQ10 administration
increased NADPH-CoQ reductase activity in the liver
and heart, and the NADPH-CoQ reductase activity in the
simvastatin and CoQ10-cotreated group was higher than that
of the simvastatin group.
Discussion
The nutritional sufficiency of CoQ is affected by both
endogenous and exogenous CoQ, and a reduction in one
source is thought to markedly affect its physiological function.
We reported previously [49] that serum CoQ10 levels in
patients on total parenteral nutrition (TPN) decreased
significantly after TPN and never reached zero following
TPN. These results suggest that the decrease in serum CoQ10
levels after TPN is dependent on dietary (exogenous) CoQ10
and that the residual serum CoQ10 levels following TPN are
dependent on biosynthesized (endogenous) CoQ10. However,
the physiological changes induced by insufficient supply of
endogenous CoQ10 have been unknown.
The CoQ biosynthesis pathway for eukaryotic cells has
already been clarified [34, 35]. CoQ shares the same bio-
synthetic pathway as cholesterol up to farnesyl pyrophos-
phate, and statins, which inhibit the rate-limiting enzyme of
cholesterol biosynthesis, block the upstream section of the
CoQ biosynthesis pathway. Therefore, statins affect CoQ
biosynthesis greatly. Furthermore, the CoQ level in the body
has been reported to decrease after the age of 20 years,
and this decrease is marked in tissues with high energy
metabolism, such as the heart [50]. Decreased CoQ10 might
be thus a serious problem, as most hypercholesterolemia
patients who take statins are elderly.
Decrease in CoQ levels induced by oral administration of
HMG-CoA reductase inhibitor
As shown in Table 1, oral administration of simvastatin
significantly decreased not only serum cholesterol levels, but
also serum and tissue CoQ9 and CoQ10 levels. Simvastatin
also decreased both reduced and oxidized forms of CoQ9 and
CoQ10. Many investigators have pointed out that statins lower
serum and tissue CoQ levels [9, 36–38], but the effects of
decreased CoQ on the body have not been fully elucidated.
Folkers et al. reported that patients on statin therapy exhibited
cardiac dysfunction [39]. The most important physiological
action of CoQ10 is to improve energy metabolism by serving
as an essential factor in the mitochondrial electron transfer
system, and this action is accepted as the physiological action
of CoQ10. Therefore, reduced CoQ levels may affect skeletal
muscles and myocardium with active energy metabolism. In
fact, muscle pain or weakness with high creatine kinase
levels is the major adverse effects of statins [2]. In the
present study, the levels of CoQ, in cytoplasm where
NADPH-CoQ reductase are present, as well as in the
mitochondria were measured (Table 1), and the results
confirmed that statin administration reduces CoQ levels in
mitochondria and cytoplasm among intracellular organelles.
Fig. 2.  Effect of simvastatin on cytosolic NADPH-CoQ reduc-
tase activities in heart and liver. The value given are
means ± SD (n =5 ) .   a)p<0.05, b)p<0.01, and c)p<0.001 vs
control (untreated) group. d)p<0.05,  e)p<0.01, and
f)p<0.001 vs simvastatin-treated group.A. Kettawan et al.
J. Clin. Biochem. Nutr.
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Decreased oxidative stress resistance due to oral adminis-
tration of HMG-CoA reductase inhibitor
In addition to energy production activation, another
important physiological action of CoQ10 is as an antioxidant
in vivo. Therefore, when simvastatin administration lowers
CoQ levels in the body, endogenous antioxidative function
may be affected to some degree. In general, orally taken
oxidized CoQ10 is absorbed by epithelial cells in the small
intestine and transported via the lymphatic system to the
liver, and is reduced by NADPH-CoQ reductase to become
H2CoQ10, which has potent antioxidant action [20–22]. In
human serum (plasma), CoQ10 is mostly present as H2CoQ10,
and even if oxidized CoQ10 is administered exogenously, the
ratio of reduced CoQ10 to total CoQ10 remains the same [51].
Therefore, H2CoQ10, which is extremely unstable in air, is
thought to exist in the body due to its role as an antioxidant.
In the present study, oral administration of statin decreased
the resistance of heart and liver mitochondria to lipid
peroxidation induced by Fe2+-ascorbate and transiently
increased the production of TBARS (Tables 2 and 3). This
increase in TBARS was alleviated by oral administration of
CoQ10. Furthermore, oral administration of CoQ10 increased
also NADPH-CoQ reductase activity, which was decreased by
statin administration (Fig. 2). On the other hand, simvastatin
also induced cessation of both spontaneous beating and
stimulation-elicited beating in cultured cardiac myocytes
(Fig. 1). This simvastatin-contractile impairment was prevented
partially by pretreatment of cultured cardiac myocytes with
10 µM CoQ10. These results suggest that by coadministering
CoQ10 and statin, sufficient amounts of H2CoQ10 are supplied
to the body and maintained, thus alleviating the decreased
oxidative stress resistance caused by statin administration.
Necessity of CoQ10 during oral administration of HMG-CoA
reductase inhibitor
In 2001, the Ministry of Health, Labour and Welfare in
Japan permitted the use of CoQ10 as a food additive as long as
no claims were made about its pharmacological effectiveness
and application. Now, many CoQ10-containing dietary and
helath supplements are commercially available in Japan.
While people mostly take CoQ10 for health maintenance
or nutritional supplementation, as the size of the elderly
population continues to increase in Japan, it is necessary to
consider to the adverse reactions caused by drugs that are
frequently prescribed to the elderly. The present study
showed that statin administration decreased the body’s
resistance to oxidative stress, and one of the factors may be
decreased CoQ levels. Therefore, we clarifies that when
administering statin, it is desirable to elevate CoQ to normal
levels, thus maintaining resistance to various oxidative
stresses.
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